National Eye Institute; Notice of Closed Meetings, 48976-48977 [2010-19940]
Download as PDF
48976
Federal Register / Vol. 75, No. 155 / Thursday, August 12, 2010 / Notices
including job estimation examples. For
the full OMB guidance, please visit:
https://www.whitehouse.gov/omb/assets/
memoranda_fy2009/m09–21.pdf.
jlentini on DSKJ8SOYB1PROD with NOTICES
Conclusion of Recovery Act-Specific
Reporting Requirements
Recipient Reporting Requirements
under PPACA
The removal of ARRA Section 1512
Reporting Requirements does not
absolve the applicant from reporting
project status as well as the other terms
and conditions set forth in the abovereferenced CPPW FOA and the Notice of
Cooperative Agreement Award.
Recipients funded with PPACA
appropriations will be required to report
project status on a semi-annual basis.
Specific reporting requirements will be
detailed in the Terms and Conditions of
the Notice of Cooperative Agreement
Award.
CFDA Number 93.520 is the PPACAspecific CFDA number for this
initiative. It will replace CFDA Number
93.724 published in the abovereferenced CPPW Funding Opportunity
Announcement (FOA).
Award Information:
Approximate Current Fiscal Year
Funding: $34,000,000.
Approximate Number of Awards: 11.
Approximate Average Award:
$3,000,000.
Fiscal Year Funds: Patient Protection
and Affordable Health Care Act of 2010.
Anticipated Award Date: 30 Sep 2010.
Budget Period: 24 months.
Project Period: 24 months.
Application Selection Process: CDC
will apply the same selection
methodology published in the CPPW
FOA, CDC–RFA–DP09–912ARRA09.
Applications will be funded in order
by score and rank determined by the
previously held review panel.
In addition, as was referenced in the
CPPW FOA, funding decisions may be
made to ensure:
• Representation of tobacco and
obesity/physical activity/nutrition
across communities, including a varied
type of interventions and evidencebased strategies.
• Geographic distribution of The
Communities Putting Prevention to
Work Initiative nationwide.
• Inclusion of communities of varying
sizes, including rural, suburban, and
urban communities.
• Inclusion of populations
disproportionately affected by chronic
disease and associated risk factors.
CDC will provide justification for any
decision to fund out of rank order.
CDC will add the following Authority
to that which is reflected in the
published Funding Opportunity:
VerDate Mar<15>2010
16:22 Aug 11, 2010
Jkt 220001
—Section 4002 of the Patient Protection
and Affordability Care Act (Public
Law 111–148.)
The effective date for this action
is August 12, 2010 and remains in effect
until the expiration of the project period
of the PPACA funded applications.
FOR FURTHER INFORMATION CONTACT:
Elmira Benson, Deputy Director, Centers
for Disease Control and Prevention,
2920 Brandywine Road, Atlanta, GA
30341, telephone: (770) 488–2802, email: EBenson@cdc.gov
SUPPLEMENTARY INFORMATION: On March
23, 2010, the President signed into law
the Patient Protection and Affordable
Care Act (PPACA). PPACA is designed
to improve and expand the scope of
health care coverage for Americans. Cost
savings through disease prevention is an
important element of this legislation
and PPACA has established a
Prevention and Public Health Fund
(PPHF) for this purpose. Specifically,
the legislation states in Section 4002
that the PPHF is to ‘‘provide for
expanded and sustained national
investment in prevention and public
health programs to improve health and
help restrain the rate of growth in
private and public sector health care
costs’’. PPACA and the Prevention and
Public Health Fund make improving
public health a priority with
investments to improve public health.
The PPHF states that the Secretary
shall transfer amounts in the Fund to
accounts within the Department of
Health and Human Services to increase
funding, over the fiscal year 2008 level,
for programs authorized by the Public
Health Services Act, for prevention,
wellness and public health activities
including prevention research and
health screenings, such as the
Community Transformation Grant
Program, the Education and Outreach
Campaign for Preventative Benefits, and
Immunization Programs.
Both ARRA and PPACA legislation
affords an important opportunity to
advance public health across the
lifespan and to reduce health disparities
by supporting an intensive community
approach to chronic disease prevention
and control. Therefore, awarding
cooperative agreements with PPACA
funds under PPHF to ABUs to carry out
CPPW objectives is consistent with the
purpose of PPHF, as stated above, to
provide for the expanded and sustained
national investment in prevention and
public health programs. Further, the
Secretary allocated funds to CDC,
pursuant to the PPHF, for the types of
activities that the CPPW initiative is
designed to carry out.
DATES:
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Therefore, the CPPW program
activities CDC proposes to fund with
PPACA appropriations are authorized
by the amendment to the Public Health
Services Act which authorized the
Prevention and Wellness Program as
embodied in CDC RFA DP09–
912ARRA09.
Dated: August 5, 2010.
Tanja Popovic,
Deputy Associate Director for Science,
Centers for Disease Control and Prevention.
[FR Doc. 2010–19907 Filed 8–11–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel, Epi R01s, Data
Analysis R21s, and K99 Applications.
Date: August 23, 2010.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, 1 Bethesda
Metro Center, 7400 Wisconsin Avenue,
Bethesda, MD 20814.
Contact Person: SAMUEL RAWLINGS,
PhD, Chief, Scientific Review Officer,
Division of Extramural Research, National
Eye Institute, National Institutes of Health,
5635 Fishers Lane, Suite 1300, MSC 9300,
301–451–2020, rawlings@nei.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Eye Institute
Special Emphasis Panel, Clinical Trials.
Date: August 24–25, 2010.
Time: 8 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, NEI
Division of Extramural Research, 5635
Fishers Lane, Bethesda, MD 20892, (Virtual
Meeting).
E:\FR\FM\12AUN1.SGM
12AUN1
Federal Register / Vol. 75, No. 155 / Thursday, August 12, 2010 / Notices
Contact Person: Daniel R. Kenshalo, PhD,
Scientific Review Officer, Division of
Extramural Research, National Eye Institute,
National Institutes of Health, 5635 Fishers
Lane, Suite 1300, MSC 9300, 301–451–2020,
kenshalod@nei.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: August 6, 2010.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
jlentini on DSKJ8SOYB1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Inherited
Disease Research Access Committee.
Date: September 7–8, 2010.
Time: September 7, 2010, 7 p.m. to 10 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Time: September 8, 2010, 8:30 a.m. to 5
p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Camilla E. Day, PhD,
Scientific Review Officer, CIDR, National
Human Genome Research Institute, National
Institutes of Health, 5635 Fishers Lane, Suite
4075, Bethesda, MD 20892, 301–402–8837,
camilla.day@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
16:22 Aug 11, 2010
Jkt 220001
[FR Doc. 2010–19939 Filed 8–11–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
[FR Doc. 2010–19940 Filed 8–11–10; 8:45 am]
VerDate Mar<15>2010
Dated: August 5, 2010.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Liver
Diseases.
Date: August 24, 2010.
Time: 2:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call.)
Contact Person: Najma Begum, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2186,
MSC 7818, Bethesda, MD 20892. 301–435–
1243. begumn@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Program
Project: Integrative Neuroscience.
Date: September 21–22, 2010.
Time: 7 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting.)
Contact Person: Brian Hoshaw, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5181,
MSC 7844, Bethesda, MD 20892. 301–435–
1033. hoshawb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Shared
Instrumentation Grant Applications.
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
48977
Date: September 22–23, 2010.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting.)
Contact Person: Patricia Greenwel, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2178,
MSC 7818, Bethesda, MD 20892. 301–435–
1169. greenwep@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 5, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–19938 Filed 8–11–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the AIDS
Research Advisory Committee, NIAID.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: AIDS Research
Advisory Committee, NIAID.
Date: September 20, 2010.
Time: 12:45 p.m. to 6 p.m.
Agenda: Reports from the Division Director
and other staff.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Salon D, Bethesda, MD 20852.
Contact Person: Rona L. Siskind, Executive
Secretary, AIDS Research Advisory
Committee, Division of AIDS, NIAID/NIH,
6700B Rockledge Drive, Room 4139,
Bethesda, MD 20892–7601, 301–435–3732.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
E:\FR\FM\12AUN1.SGM
12AUN1
Agencies
[Federal Register Volume 75, Number 155 (Thursday, August 12, 2010)]
[Notices]
[Pages 48976-48977]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-19940]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Eye Institute Special Emphasis
Panel, Epi R01s, Data Analysis R21s, and K99 Applications.
Date: August 23, 2010.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Hyatt Regency Bethesda, 1 Bethesda Metro Center, 7400
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: SAMUEL RAWLINGS, PhD, Chief, Scientific Review
Officer, Division of Extramural Research, National Eye Institute,
National Institutes of Health, 5635 Fishers Lane, Suite 1300, MSC
9300, 301-451-2020, rawlings@nei.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Eye Institute Special Emphasis
Panel, Clinical Trials.
Date: August 24-25, 2010.
Time: 8 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, NEI Division of Extramural
Research, 5635 Fishers Lane, Bethesda, MD 20892, (Virtual Meeting).
[[Page 48977]]
Contact Person: Daniel R. Kenshalo, PhD, Scientific Review
Officer, Division of Extramural Research, National Eye Institute,
National Institutes of Health, 5635 Fishers Lane, Suite 1300, MSC
9300, 301-451-2020, kenshalod@nei.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.867,
Vision Research, National Institutes of Health, HHS)
Dated: August 6, 2010.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-19940 Filed 8-11-10; 8:45 am]
BILLING CODE 4140-01-P